(a) Losses in Associate

Set out below is the summarised financial information of Medical Ethics Pty Ltd for the year ended 30 June 2018 (2017: period 30 March 2017 to 30 June 2017), which is accounted for using the equity method. This is not Dechra Pharmaceuticals PLC's share of the results.

Pre-tax loss from continuing operations(0.1)(0.1)
Post-tax loss from continuing operations(0.1)(0.3)
Non-current assets1.9
Current assets5.25.5
Non-current liabilities
Current liabilities(0.4)(0.5)
Net assets of associate6.75.0

(b) Interest in Associate

1 July 201710.8
Share of underlying loss after tax(0.1)(0.1)
Share of amortisation of intangible asset identified on acquisition(0.2)(0.1)
30 June 201810.510.8

On 30 March 2017 the Group acquired a 33.0% interest in Medical Ethics Pty Ltd for AUD$18.0 million (£11.0 million), which is the holding company of Animal Ethics Pty Ltd. The company is incorporated in Australia, which is also the principal place of business. The registered address is c/o Level 3, 649 Bridge Road, Richmond, Victoria 3121, Australia. The company has share capital consisting solely of ordinary shares, which are directly owned by the Group. Medical Ethics Pty Ltd is a private company and there is no quoted market price available for its shares. There are no contingent liabilities relating to the Group's interest in the associate.

Following the acquisition of Medical Ethics Pty Ltd, the disclosure of the final fair values of the assets and liabilities acquired were included in the financial statements for the year ended 30 June 2017. The Group's share of the loss arising from its investment in Medical Ethics includes the effect of amortising the fair value adjustments.

(c) Reconciliation of summarised financial information presented to the carrying amount of its interest in associates

Opening interest in associate2.2
Fair value of associate acquired
Post-tax loss from continuing operations(0.1)
Amortisation of notional intangible asset recognised on acquisition(0.2)
Interest in associate1.9
Carrying value of investment in associate10.5